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Abstract
The human ZFP36 zinc finger protein family consists of ZFP36, ZFP36L1, and ZFP36L2. These proteins regulate various
cellular processes, including cell apoptosis, by binding to adenine uridine rich elements in the 39 untranslated regions of
sets of target mRNAs to promote their degradation. The pro-apoptotic and other functions of ZFP36 family members have
been implicated in the pathogenesis of lymphoid malignancies. To identify candidate mRNAs that are targeted in the pro-
apoptotic response by ZFP36L1, we reverse-engineered a gene regulatory network for all three ZFP36 family members
using the ‘maximum information coefficient’ (MIC) for target gene inference on a large microarray gene expression dataset
representing cells of diverse histological origin. Of the three inferred ZFP36L1 mRNA targets that were identified, we
focussed on experimental validation of mRNA for the pro-survival protein, BCL2, as a target for ZFP36L1. RNA
electrophoretic mobility shift assay experiments revealed that ZFP36L1 interacted with the BCL2 adenine uridine rich
element. In murine BCL1 leukemia cells stably transduced with a ZFP36L1 ShRNA lentiviral construct, BCL2 mRNA
degradation was significantly delayed compared to control lentiviral expressing cells and ZFP36L1 knockdown in different
cell types (BCL1, ACHN, Ramos), resulted in increased levels of BCL2 mRNA levels compared to control cells. 39 untranslated
region luciferase reporter assays in HEK293T cells showed that wild type but not zinc finger mutant ZFP36L1 protein was
able to downregulate a BCL2 construct containing the BCL2 adenine uridine rich element and removal of the adenine
uridine rich core from the BCL2 39 untranslated region in the reporter construct significantly reduced the ability of ZFP36L1
to mediate this effect. Taken together, our data are consistent with ZFP36L1 interacting with and mediating degradation of
BCL2 mRNA as an important target through which ZFP36L1 mediates its pro-apoptotic effects in malignant B-cells.
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Introduction
The human ZFP36 protein family consists of three widely-
expressed members, namely, ZFP36 (TIS11, TTP, Nup475,
GOS24), ZFP36L1 (Tis11b, Berg36, ERF-1, BRF-1), and
ZFP36L2 (Tis11d, ERF-2, BRF-2) [1–3]. A fourth family member
described in rodents, Zfp36l3, displays placental-specific expres-
sion, but is not detectably expressed in any human tissues [4].
ZFP36-family proteins have also been identified and characterised
in some other species such as Xenopus, Drosophila and yeast [5–7].
These proteins contain two tandemly repeated zinc finger motifs
and function to regulate gene expression at the post-transcriptional
level by binding to adenine uridine (AU) rich elements (AREs) in
the 39 untranslated region (39UTR) of sets of mRNAs and
mediating ARE-dependent mRNA decay [1–3]. In mammals,
ZFP36 family members have been shown to function in regulating
development, cell differentiation, tumourigenesis, the inflamma-
tory response and apoptosis by targeting an extensive overlapping
repertoire of mRNAs. These have been best characterised in the
inflammatory/immune response in which all three ZFP36 family
members elicit rapid downregulation of key cytokines via
destabilisation of their mRNAs (reviewed in [1–3]). Members of
the ZFP36 family also target mRNAs encoding key transcription
factors, such as STAT5b in the regulation of erythropoiesis [8] and
PRDM1/Blimp1 in terminal plasmacytoid differentiation of B
cells [9].
We originally reported on the pro-apoptotic function of
ZFP36L1 in Ramos Burkitt B lymphoma cells [10] and more
recently in Rituximab-induced apoptosis of B-chronic lymphocytic
leukaemia cells (BCLL) [11] from which the human ZFP36L1 gene
was originally isolated as an early response gene cDNA [12].
Overexpression of ZFP36 family members has been shown by
other laboratories to induce apoptosis in a variety of other
mammalian cell lines including HeLa, U20S, SAOS2, and 3T3
[13,14]. Induction of apoptosis by all three ZFP36 family members
is completely abrogated in the presence of Bcl-2 or CrmA [13].
ZFP36 synergistically induces apoptosis with TNF-a in 3T3 cells
and the zinc fingers and the N-terminal domain of ZFP36 are
absolutely required for this effect [14]. Mutant ZFP36 (TIS11)
lacking the zinc finger motifs fails to induce apoptosis and is
localised to the nucleus, whereas the wild type ZFP36/TIS11 is
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localised in the cytoplasm [14]. Induction of apoptosis by ZFP36
family proteins therefore appears to require intactness of the zinc
finger motifs and presumably mRNA binding. However, the
identities of mRNAs that are targeted by ZFP36 family members
in mediating their pro-apoptotic effects are currently unknown.
To identify candidate mRNAs that are targeted in the pro-
apoptotic response by ZFP36L1, we reverse-engineered a gene
regulatory network for ZFP36 family members using the
‘maximum information coefficient’ (MIC) for target gene inference
[15] Of the final set of three inferred anti-apoptosis ZFP36L1
targets identified by this analysis, we focussed on experimental
validation of mRNA for the well-characterised BCL2 protein and
here present evidence that BCL2 mRNA is a target for ZFP36L1
protein. Targeting BCL2 mRNA, and potentially other anti-
apoptotic mRNAs, may explain at least in part the reported pro-
apoptotic effects of ZFP36L1 protein.
Materials and Methods
Data mining of microarray expression gene expression
data
To identify mRNAs that are regulated by ZFP36 family
members at a global level, a gene expression microarray dataset
comprised of 206 cell line samples representing cell types of diverse
histological origin was downloaded from NCBI Gene Expression
Omnibus database (Affymetrix; GSE10843, http://www.ncbi.
nlm.nih.gov/geo). The data was fRMA-normalised [16] and
barcode-filtered [17] to generate probeset values representing
10016 unique protein-coding genes. An unsupervised reverse
engineering of gene regulatory networks approach was employed
to determine pair-wise statistical dependences between expression
of each ZFP36 family member and all other genes in the dataset.
Algorithms used were Maximum Information Coefficient (MIC),
Mutual Information (MI) and Linear Regression (LR). MIC and
LR values were computed using the maximal information-based
nonparametric exploration (MINE) statistics package in Biocon-
ductor, R [15], using a threshold cut-off MIC score corresponding
to a false discovery rate (FDR) q value (calculated using 36107
permutations) of 0.01. MI values were computed using ‘ARACNE’
(Algorithm for the Reconstruction of Accurate Cellular Networks)
[18], v2 with a data processing inequality tolerance (DPI) value of
1.0 as implemented in the GenePattern (v3.6.0) suite of software
tools [19]. Network inference performance was evaluated/
validated by gene set enrichment analysis (GSEA) [20] on inferred
ZFP36 target genes, ranked by inference metric, using two
independent gene sets representing experimentally-identified
ZFP36 target genes in fibroblasts from ZFP36/Tis11-knock-out
mice. The first of these [21] comprised a 237 gene set for
transcripts that are significantly (FDR,0.01) up-regulated in
ZFP36/Tis11-knock-out versus wild type fibroblasts, while the
second comprised a 152 gene set representing transcripts that
display a decreased rate of decay (stabilisation) in ZFP36/Tis11-
knock-out fibroblasts after serum stimulation and actinomycin D
treatment in time-course microarray experiments [22]. Genes
displaying a significant increase in stabilisation in ZFP/Tis11-
knock-out cells were identified using the maSigPro algorithm [23]
in Bioconductor R on the microarray dataset, GSE5324 [22] using
a FDR cut-off value of 0.01.
MIC-inferred target genes for all three ZFP36 family members
were filtered using the ‘ARED’ database [24] for the presence of
two or more copies of the consensus 13 bp AU-rich element motif:
WWWU(AUUUA)UUUW in the 39-untranslated region (UTR)
that is present in most characterised ZFP36/Tis11 target mRNAs
[25,26]. Target genes were further filtered by the sign of the LR
coefficient to identify those whose expression is inversely correlated
with each of the ZFP36 family members (candidates for targeted
degradation). Gene Ontology (GO) enrichment analysis was
performed on the final combined list of ZFP36 family targets
using the GSEA on-line database (http://www.broadinstitute.org/
gsea/index.jsp) [20]. Network graphs were constructed and
visualised in Cytoscape v2.8 [27]. Statistical analysis of gene
overlap by hypergeometric distribution was performed using the
‘phyper’ algorithm in Bioconductor R.
Cell Culture
Murine B cell leukemia BCL1 cells were obtained from the
European collection of cell cultures (ref. No. 90061904) and grown
in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-
Glutamine, 50 U/mL penicillin streptomycin, 1% sodium pyru-
vate, 1% non-essential amino acids and 0.05 mM 2-mercaptoeth-
anol. Ramos human Burkitt lymphoma B cells (European
collection of cell cultures ref. No. 85030802) and ACHN human
renal carcinoma cells (NCI-Frederick DCTD Tumor/Cell Line
Repository, 0503808) were grown in RPMl 1640 medium
(Invitrogen) supplemented with 10% FBS, 50 U/mL penicillin
streptomycin, and 2 mM L-Glutamine. All cells were cultured at
37uC, in a humidified CO2 incubator. For some experiments,
Ramos cells were serum starved in FBS-free medium for 16 hours
and stimulated with 30 nM of Phorbol 12-Myristate 13-Acetate
(PMA) for 3 hours.
Modulation of ZFP36L1 levels using a ShRNA expressing
lentivirus in different cell types
A ZFP36L1-ShRNA lentivirus was constructed by cloning a
ZFP36L1 ShRNA into the pSicoR lentiviral vector [28] as
outlined previously [9]. Stable mammalian cell lines containing the
ZFP36L1-ShRNA, empty lentivirus or a scrambled version of the
ZFP36L1-ShRNA were prepared following transduction of cells
with virus and cell sorting GFP positive cells on a flow cytometer
(BCL1 and Ramos cells). Transduction efficiency was very high for
ACHN cells (.95%) and no cell sorting was required. Efficiency of
ZFP36L1 knockdown was assessed by qRT-PCR and Western
Blot analysis. For details on oligonucleotides designed for
ZFP36L1 ShRNA and scramble sequence please see [9].
Bacterial Expression of ZFP36L1 and protein purification
using Ni2+-Affinity Chromatography
Human ZFP36L1 protein was expressed in E.coli and purified
using a protocol similar to one previously published [29]. A cDNA
encoding the open reading frame of human ZFP36L1 was cloned
into pET15b plasmid. Overnight cultures of E.coli BL21 (DE3)
(Agilent, Stockport, UK) transformed with recombinant plasmids
were harvested, the cell pellet went through one cycle of freezing at
270uC and thawing at 37uC and was resuspended in 20 ml of lysis
buffer (5 mM Imidazole, 0.5 M NaCl, 20 mM NAPO4, 1 mg/ml
Lysosyme, 1 mM PMSF, and 5 U/ml DNase; pH 7.4). The cells
were disrupted by a brief sonication and their pellets containing
inclusion bodies were resuspended overnight at 4uC in 100 ml of
denaturing buffer (8 M Urea, 0.5 M NaCl, and 20 mM NAPO4;
pH 8.0). Solubilized denatured proteins were recovered in the
supernatant following centrifugation at 18 000 rpm for 15 min at
4uC. Using a Pharmacia LKB Pump P-1 (GE Healthcare, Bio-
Sciences AB, Uppsala, Sweden), a HiTrap Chelating column (GE
Healthcare) was washed with 300 ml DH2O, charged with 30 ml
of 0.1 M NiCl charging buffer, and again washed with 100 ml of
deionised water. The column was equilibrated in 100 ml of
denaturing buffer (8 M Urea, 0.5 M NaCl, and 20 mM NAPO4;
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pH 8.0) and the urea-solubilized proteins were loaded onto the
nickel-conjugated column to allow binding of the His-tagged
protein to the nickel column. 100 ml of buffer A (20 mM
Imidazole, 8 M Urea, 0.5 M NaCl, and 20 mM NAPO4;
pH 8.0) was used to wash the column. Bound proteins were
refolded on the column by slowly decreasing the urea concentra-
tion of denaturing buffer from 8 M to 0 M urea (8 M, 6 M,
4.5 M, 3 M, 2 M, 1 M, 0.5 M, 0.2 M, 0.1 M, 0 M). A gradient
volume of 20 ml and a flow rate of 1 ml/min were used for
refolding step. The refolded recombinant protein was eluted with
EDTA buffer (500 mM NaCl, 20 mM NAPO4, and 50 mM
EDTA, and 16Roche Protease Inhibitor Cocktail; pH 7.4) after
the gradient has come to its endpoint. The eluted protein was
dialysed at 4uC against 3 L of PBS (pH 7.4). Protein concentration
was measured by a Bicinchoninic protein assay (Sigma, Poole,
UK).
Western blotting
Cells were washed with ice-cold PBS and lysed on ice for
30 min in 100 ml of Nonidet P-40 buffer (1% NP - 40, 20 mM Tris
HCl (pH 7.4), 150 mM NaCl, 2 mM MgCl2, and 1 mM EDTA)
containing Complete Protease Inhibitor Cocktail (Roche) and
1 mM of phenylmethylsulfonyl fluoride. Cytoplasmic protein
extract was separated from nuclei by centrifugation at 13 000
RPM at 4uC for 10 min. Protein extracts were separated by
SDSPAGE Electrophoresis and electrotransferred onto nitrocel-
lulose membranes which were blocked overnight at 4uC in
blocking buffer containing 5% milk powder and TTBS buffer
(23 mM Tris base, 0.5 M NaCl, and 0.05% Tween-20). Nitrocel-
lulose membranes were incubated with appropriate dilution of the
following primary antibodies for 1 hour; purified rabbit polyclonal
anti-ZFP36L1/L2 (cat. no. 2119, Cell Signaling, Danvers, MA,
USA), purified rabbit anti-BCL2 antibody (cat. No. #2876, Cell
Signalling Technology, MA, USA)) or purified rabbit anti-human
HSP90 (cat. no. SC-7947, Santa Cruz BiotechnologySanta Cruz,
CA, USA) as a loading control. Following this incubation,
membranes were washed and incubated with horseradish perox-
idise-conjugated swine anti-rabbit immunoglobulin for 1 hour.
Chemiluminescent signals on membranes were detected using
SuperSignal West Femto Substrate (Pierce, Rockford, IL, USA)
and exposed to XRayfilms (Kodak Biomax MS, Sigma). The films
were developed in a Xograph Compactx4 film processor (Xograph
Imaging Systems Ltd. Tetbury, UK).
RNA Electrophoretic Mobility Shift Assay (REMSA)
32P-labeled and unlabeled mRNA probes were made in vitro
using Riboprobe In Vitro Transcription Systems (Promega, South-
ampton, UK) in the presence or absence of 40 mCi of [a-32P]rUTP
(GE Healthcare) respectively. The BCL2 ARE probe was
generated using the plasmidPCRII/bcl-2 ARE [30]. The resulting
probe was separated from unincorporated nucleotides using
ProbeQuant G-50 Micro Columns (GE Healthcare). E.coli-
expressed purified ZFP36L1 protein (10–100 ng) or cell protein
cell lysates (30 mg) were incubated with 50 000 to 100 000 cpm of
a-32P-labeled RNA probes, corresponding to approximately 30–
100 fmol RNA. The proteins were incubated with RNA probes for
20 min on ice in RNA-binding buffer containing 20 mM HEPES
(pH 7.6), 3 mM MgCl2, 40 mM KCl, 2 mM DTT, and 5%
Glycerol in a total volume of 20 ml. RNase T1 and heparan sulfate
(Sigma) were added to final concentrations of 50 U/ml and 5 mg/
ml, respectively, and incubated on ice for another 20 min. RNA-
protein complexes were resolved by electrophoresis (150 V for
3 hours at 4uC) on a 4% nondenaturing polyacrylamide gel using
a Hoefer SE600 electrophoresis unit (Hoefer Scientific, Holliston,
MA, USA). The gel was dried on a gel dryer (Hoefer SE1160 Gel
Dryer), exposed to X-ray film (Kodak BioMax MS) and
developed.
Quantitative RT-PCR analysis
Total RNA was extracted using an RNeasy Mini Kit (Qiagen,
Crawley, UK). 1 mg of total RNA was reverse-transcribed for
cDNA synthesis using a QuantiTect Reverse Transcription kit
(Qiagen). Quantitative RT-PCR was performed using an ABI
Prism 7000 Sequence Detection System (Applied Biosystems,
Carlsbad, CA, USA), in a total volume of 25 ml containing cDNA,
26QuantiTect SYBR Green Master mix (Qiagen), and 0.5–1 mM
of each oligonucleotide primer. The primer pairs used for the
following genes were: mouse Bcl-2 QuantiTect primer set
QT00156282 (Roche, Basel,
Switzerland), mouse zfp36l1 forward 59-TTCACGACACACCA-
GATCCT-39 and reverse 59-TGAGCATCTTGTTACCCTTGC-
39, mouse IL-3 forward 59-ATTCTACATGGTCCACCTTAACG-
A-39 and reverse 59-GGCTGAGGTGGTCTAGAGGTT-39mouse
b actin forward 59-CTAAGGCCAACCGTGAAAAG-3’ and reverse
5’-ACCAGAGGCATACAGGGACA-39, human ZFP36L1 forward
59-GATGACCACCACCCTCGT-39 and reverse 59-CTGGGAG-
CACTATAGTTGAGCA-39, human b actin forward 59-CCAAC-
CGCGAGAAGATGA-39 and reverse 59-CCAGAGGCGTACAG-
GGATAG-39, human Bcl-2 forward 59-AGTACCTGAACCGG-
CACCT-39 and reverse 59-GGCCGTACAGTTCCACAAA-39. All
PCR reactions were carried out in triplicate. The PCR program
consisted of 1 initial cycle of 15 min at 95uC, 40 cycles of 15 sec at
95uC, 15 sec at 60uC, and 30 sec at 72uC. The relative changes in
gene expression levels were calculated using the 2–DDCT method
[31].
39UTR luciferase reporter assay
Human BCL2 ARE sequences from plasmids PCRII/bcl-2
ARE+ and PCRII/bcl-2 mutARE [30] were cloned into the
pmirGlo luciferase reporter vector (Promega) to generate BCL2
ARE+ and mutBCL2 ARE luciferase reporter vectors. BCL2 ARE+
contains a more extensive region of BCL2 39 UTR sequences
surrounding the AU-rich core than BCL2 ARE which was used in
the REMSA analysis (see above) and mutBCL2 ARE is similar to
BCL2 ARE+ but lacks the AU-rich core region present in BCL2
ARE+ [30]. 24 h prior to transfection HEK 293T cells (26105
cells/ml) were seeded per well of a 12 well plate. Cells were then
transfected with 100 ng of BCL2 ARE probes in luciferase reporter
vector with 200 ng of human ZFP36L1 expression vector
(pcDNA6ZFP36L1) or ZFP36L1 with a zinc finger domain
mutation (mutZFP36L1) or empty vector (pcDNA3). Cells were
left for 24 h after transfection, then cell lysates were prepared, and
luciferase and renilla signals measured using the Dual luciferase
reporter assay system (Promega) on a Fluostar Optima (BMG,
Labtech) plate reader.
MTT assay to measure ionophore-induced Ramos cell
viability
An MTT cell viability assay was carried out to measure calcium
ionophore-induced cell death in Ramos cells under different
conditions. ZFP36L1 siRNA oligonucleotide (Stealth RNAi,
Invitrogen) and control siRNA (Stealth negative control RNAi,
Invitrogen) were transfected into Ramos cells using Viromer blue
transfection reagent (Lipocalyx, Halle, Germany) according to the
manufacturer’s instructions. 24 h later cells were treated with an
optimum concentration of ionophore (A23187, 150 nM) [10] and
then, after 20 h incubation, MTT (0.5 mg/ml) was added to cells.
BCL2 mRNA Regulation by ZFP36L1
PLOS ONE | www.plosone.org 3 July 2014 | Volume 9 | Issue 7 | e102625
After 4 h incubation, MTT levels were measured on a spectro-
photometer at 490 nm.
Ad hoc Statistical Analysis
The Student T test was used to determine differences between
samples. Values were expressed as mean 6SEM.
Results
Inference of ZFP36 apoptotic target mRNAs from gene
expression data
To identify candidate mRNAs that are targeted in the pro-
apoptotic response by ZFP36 proteins, we reverse-engineered a
gene regulatory network for all three ZFP36 family members using
three different algorithms (maximum information coefficient,
MIC; mutual information, MI; linear regression, LR) to calculate
pair-wise statistical dependency from a large microarray gene
expression dataset. The performance of each algorithm in terms of
accuracy/reliability was evaluated by gene set enrichment analysis
(GSEA) between inferred ZFP36 targets and experimentally-
identified ZFP36 targets represented by two independent gene sets
obtained from Zfp36/Tis11 knock-out fibroblasts (see Materials
and Methods). As shown in Table 1, the MIC algorithm [15] out-
performed MI and LR calculations for target gene inference, with
highly significant GSEA Kolmogorov-Smirnov statistical scores on
each of the two independent experimental gene sets. Fig. 1 shows
the GSEA profiles obtained with rank-ordered MIC-inferred
ZFP36 targets. The MIC algorithm was therefore used for
subsequent analysis on all three ZFP36 family members.
After statistical thresholding and filtering for the subset of MIC-
inferred targets that contain ARE elements in their 39UTRs, the
list of candidate target genes for ZFP36 family members (Table S1)
was found to be over-represented in GO terms for several
biological processes that included ‘‘apoptosis/programmed cell
death’’ (Table S2). Fig. 2A shows a network graph view of the
inferred target genes for each ZFP36 family member. While each
ZFP36 family member was inferred to target its own set of unique
mRNAs, there was a highly significant overlap of targets that were
common in pair-wise comparisons of different ZFP36 family
members (P =,1e-7, by hypergeometric distribution). The
inferred target genes were finally filtered to identify those encoding
proteins with GO terms that included ‘‘apoptosis/programmed
cell death’’ (Table S2) that are known to negatively regulate
programmed cell death. The resulting network graph depicting
inferred pro-survival target mRNAs that are negatively regulated
in the pro-apoptotic response of ZFP36 family members is shown
in Fig. 2B. ZFP36 and ZFP36L1 share the same three targets
(BCL2, BNIP2, OPA1) while ZFP36L2 shares BNIP2 and OPA1
with ZFP36/ZFP36L1 and also targets four additional mRNAs
(BCL10, NOTCH2, BIRC3, HDAC1). For a full description of these
inferred targets, see Table S1. Of the seven predicted targets, four
(BCL-2, BCL10, BIRC3, BNIP2) function in well-defined apoptosis
pathways while the other three predicted targets (HDAC1, OPA1,
NOTCH2) have additional more general roles in controlling gene
expression and/or developmental pathways.
ZFP36L1 interacts with the BCl2 ARE and mediates its
degradation
We focussed on experimental validation of the well-charac-
terised BCL2 protein as a target (shared by both ZFP36 and
ZFP36L1 - see Fig. 2B) with ZFP36L1. To this end, we first
produced recombinant human His-tagged ZFP36L1 protein in E.
coli and purified it from inclusion bodies by nickel column
chromatography (Fig. S1). Recombinant expressed ZFP36L1
protein was used in RNA electrophoretic mobility shift assay
(REMSA) experiments to test whether ZFP36L1 interacted with
the BCL2 ARE. Fig. 3 shows the results of these experiments. A
previously characterised BCL2 ARE probe (see Methods) effec-
tively formed a complex with ZFP36L1 protein (Fig. 3A). Inclusion
of a specific antibody to ZFP36L1 inhibited complex formation.
Non-specific (control) antibody did not affect levels of complex
formation with BCL2 ARE. Fig. 3B shows the effect of increasing
amounts of cold competitor BCL2 ARE (lanes 2–4) on ZFP36L1/
BCL2 ARE complex formation. Increasing concentrations of cold
competitor BCL2 ARE probes decreases levels of complex
formation in a dose-dependent manner. Fig. 3C shows the dose
response relationship between recombinant ZFP36L1 protein
input and complex formation. Complex formation was lost when
5 ng or less of recombinant ZFP36L1 protein was included in the
REMSA reaction.
In further experiments, we investigated whether endogenous
ZFP36L1 could also be shown to bind to the BCL2 ARE. For these
Figure 1. Validation of ZFP36 target genes inferred from MIC
analysis of microarray gene expression data. Gene set enrich-
ment analysis [20] profiles are shown for 10016 genes, rank-ordered by
MIC score. Normalised Kolmogorov-Smirnov enrichment scores (NES)
and false discovery rate q values (FDR) are shown. (A) using a gene set
(n = 237) representing mRNAs that are significantly up-regulated in
Tis11/ZFP36-knock-out mouse fibroblasts [21], (B) using a gene set
(n = 152) representing mRNAs that display a significantly decreased rate
of degradation in Tis11/ZFP36-deficient mouse fibroblasts [22].
doi:10.1371/journal.pone.0102625.g001
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experiments, cell lysates from Ramos Burkitt lymphoma B cells,
which express high levels of ZFP36L1 in response to PMA
stimulation, were used. Fig. 3D shows levels of ZFP36L1
expression in Ramos cells before and 3 hours after stimulation
with PMA (30 nM). ZFP36L1 expression is seen as a series of
bands, representing different structural forms of the protein at 40–
45 kD range on the Western blot. Levels of ZFP36L1 protein were
low before stimulation with PMA but were increased several-fold
following PMA stimulation. Fig. 3E shows results from a REMSA
assay carried out using cell lysates from PMA stimulated Ramos
cells. Complex formation was seen using protein lysates from PMA
stimulated cells. Addition of anti-ZFP36L1 antibody to the
REMSA reactions reduced levels of complex formation whereas
inclusion of a non-specific control antibody did not affect levels of
complex formation (Fig. 3E). REMSA analyses therefore shows
that ZFP36L1 interacts with the BCL2 ARE.
Evidence for a role for ZFP36L1 in BCL2 mRNA degradation
came from mRNA degradation analysis following actinomycin D
treatment in two different murine leukemia BCL1 cell lines, one of
which had been stably transduced with a lentiviral vector
expressing Zfp36l1-ShRNA and a second BCL1 cell line that
had been stably transduced with control (empty vector) lentivirus
[9]. Fig. 4A shows effective knockdown of Zfp36l1 protein
expression in the ShRNA transduced BCL1 line whereas control
Table 1. Comparison between gene set enrichment validation results for ZFP36-inferred target genes obtained using different
metrics of statistical-dependency.
METHOD Up-regulated in KOa Stabilised in KOb
NES FDR NES FDR
MIC 2.407 ,0.00001 1.997 0.003
MI 1.193 0.042 1.194 0.102
LR 1.098 0.086 0.960 0.645
Abbreviations: KO, Tis11/ZFP36 knock-out mouse fibroblasts; NES, normalised enrichment score from Kolmogorov-Smirnov gene set enrichment analysis; FDR, false
discovery rate q value from Kolmogorov-Smirnov gene set enrichment analysis; MIC, maximum information coefficient; MI, mutual information, LR, linear regression
coefficient.
aGene set representing 237 mRNAs displaying significant up-regulation in expression in fibroblasts from Tis11/ZFP36-deficient mouse fibroblasts [21].
bGene set representing 152 mRNAs displaying significantly decreased rate of degradation in Tis11/ZFP36-deficient mouse fibroblasts [22].
doi:10.1371/journal.pone.0102625.t001
Figure 2. Reverse-engineering a gene regulatory network for ZFP36 family identifies BCL2mRNA as a direct target for ZFP36L1. (A)
Network graph image of inferred target mRNAs for ZFP36 family members. Edges represent regulatory interactions inferred from significant pair-wise
statistical dependences calculated from MIC scores (see Table S2). A force-directed Cytoscape layout is shown. Identification of BCL2 mRNA as a direct
target for ZFP36L1. (B) Candidate anti-apoptotic targets for ZFP36 family members identified from a reconstructed regulatory network. A hierarchical
Cytoscape layout is shown.
doi:10.1371/journal.pone.0102625.g002
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lentivirus expressing cells had equivalent levels of Zfp36l1
expression to wild-type BCL1 cells. Following actinomycin D
treatment, BCL2 mRNA degradation was monitored by qRT-
PCR analysis. The half-life of BCL2 mRNA was estimated to be
approximately 2.6 hours in control cells; degradation was signif-
icantly delayed in Zfp36l1 ShRNA BCL1 cells (Fig. 4B).
The effect of ZFP36L1 mRNA knockdown on BCL2 expression
level was also investigated by lentiviral transduction of ZFP36L1
ShRNA in BCL1 and two other cells lines. Fig. 4C shows levels of
ZFP36L1 mRNA knockdown in BCL1, Ramos human Burkitt
lymphoma cells and ACHN human renal carcinoma cells
compared to control cells. ACHN cells express high levels of
ZFP36L1 mRNA and appreciable levels are also expressed in
BCL1 cells with much lower levels expressed in Ramos cells.
Significantly, BCL2 mRNA levels were correspondingly higher in
BCL1, ACHN and Ramos cells in ZFP36L1 ShRNA transduced
compared to control cells (Fig. 4D). As a positive control mRNA
target for ZFP36L1 knockdown, we also observed higher levels of
mRNA for the previously published ZFP36L1 target, IL-3 [1], in
ZFP36L1 ShRNA transduced BCL1 cells compared to control
BCL1 cells (Fig. S2).
We also confirmed that BCl2 protein expression was higher in
ZFP36L1 ShRNA transduced Ramos cells compared to control
cells (Fig. 4D). We previously reported that BCL2 over-expression
protected Ramos cells from ionophore-induced cell death [32].
SiRNA oligonucleotide mediated ZFP36L1 knockdown also
protected Ramos cells from ionophore-induced cell death
(Fig. 4E) an effect, we previously observed using an antisense
ZFP36L1 construct [10], that is consistent with the increased
BCL2 expression seen in ZFP36L1-knockdown cells. We previ-
ously reported that ZFP36l1 is highly expressed in human tonsillar
germinal centres [9] where BCL2 expression is known to be very
low (confirmed in immunohistological analysis – data not shown)
consistent with an inverse relationship between expression of these
two proteins in a physiological context.
Two BCL2 ARE constructs (BCL2 ARE+ and mutant BCL2
ARE, lacking the AU core binding sequence - see Methods [30])
were cloned into the pmirGlo luciferase reporter vector (Promega).
BCL2 ARE constructs were transfected with either empty vector
(pcDNA3), vector containing ZFP36L1 (pcDNA6.ZFP36L1), or
vector containing a zinc finger mutant version of ZFP36L1
(pcDNA6.mutZFP36L1) (see Methods). Fig. 5A shows high level
expression of both ZFP36L1 and mutZFP36L1 in transfected
HEK293T cells compared to vector alone transfected cells.
39UTR luciferase reporter assays using these constructs showed
that in ZFP36L1 transfected cells, luciferase levels were signifi-
cantly lower than in mutZFP36L1 or empty vector transfected
cells (Fig. 5B). Furthermore, removal of the core AU rich region
from the BCL2 ARE significantly inhibited ZFP36L1 mediated
degradation of the BCL2 ARE (Fig. 5C), consistent with this region
being important for ZFP36L1 binding to the BCL2 ARE.
Figure 3. RNA electrophoretic mobility shift analyses of
ZFP36L1 binding to the BCL2 ARE. (A) REMSA analysis of
recombinant ZFP36L1 binding to BCL2 ARE RNA probes (see Methods).
50 ng of purified recombinant ZFP36L1 protein was incubated with 32P-
labeled BCL2 ARE. The specificity of RNA-protein complexes were
examined by addition of 80 ng of anti-ZFP36L1 antibody (Cell Signaling
Technology rabbit-anti-human ZFP36L1/L2 antibody) or a non-specific
control (rabbit IgG) for 10 min prior to addition of radiolabeled probes
as indicated (B) REMSA analysis of recombinant ZFP36L1 binding to
BCL2 ARE probes, using cold competition. 50 ng of purified recombi-
nant ZFP36L1 protein was incubated with 32P-BCL2 ARE (lane 2) or
ZFP36L1 and 56 (lane 3) and 106molar (lane 4) excess of unlabeled
cold competitor BCL2 ARE probe. Lane 1: BCL2 ARE probe only. (C)
REMSA analysis of recombinant ZFP36L1 binding to BCL2 ARE probe,
using decreasing amounts of recombinant ZFP36L1 protein. Decreasing
amounts of the purified ZFP36L1 protein (50–2.5 ng) were incubated
with radiolabeled BCL2 ARE probe. Lane 1: BCL2 ARE probe alone; Lane
2, 3, 4, and 5: BCL2 probe and 50, 25, 5, and 2.5 ng of recombinant
ZFP36L1 protein respectively. The REMSA experiments described above
were repeated at least twice with similar results. (D) Western blot
analysis of ZFP36L1/L2 protein expression in non-induced and PMA-
induced Ramos cells. Ramos B cells were serum-starved for 16 hours
either unstimulated or stimulated with 50 nM PMA for 3 hours Lane 1:
Cell lysate from non-induced Ramos cells; Lane 2: Cell lysate from PMA-
induced Ramos cells. Anti-human ZFP36L1/L2 antibody (Cell Signaling
Technology rabbit-anti- human ZFP36L1/L2 antibody) was used to
detect ZFP36L1/L2 expression. An anti-HSP90 antibody was used as a
control for protein loading on the gel. The data shown is representative
of similar results obtained in two independent experiments. (E) PMA-
induced lysates (30 mg) of Ramos B cells were incubated with
radiolabeled BCL2 ARE and 80 ng of anti-ZFP36L1 antibody (Cell
Signaling Technology rabbit-anti- human ZFP36L1/L2 antibody) and
non-specific (rabbit IgG) antibodies respectively. Lane 1: BCL2 ARE
probe alone; Lane 2: BCL2 ARE probe incubated with PMA-induced
Ramos lysate; Lane 3: BCL2 ARE probe incubated with PMA-induced
Ramos lysate and anti-ZFP36L1/L2 antibody; Lane 4: BCL2 ARE probe
incubated with PMA-induced Ramos lysate and non-specific control
antibody. * indicates specific bands.
doi:10.1371/journal.pone.0102625.g003
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Discussion
BCL2, a cell survival protein whose dysregulation is a hallmark
of a number of malignancies, is controlled by transcriptional, post-
transcriptional and post-translational mechanisms (reviewed in
[33]). Significantly, three AU-rich-RNA-binding proteins have
previously been shown to regulate BCL2 levels via binding to ARE
39 UTR elements in the BCL2 mRNA: AUF1 functions to
destabilise BCL2 mRNA [30,34], nucleolin (acting antagonistically
with AUF1) stabilises the BCL2 mRNA [34–36] while HUR acts
to both stabilise and enhance translational efficiency of BCL2
mRNA [37] (reviewed in [2]). Our data reveal a role for a fourth
RNA-binding protein, ZFP36L1, in mediating BCL2 post-
transcriptional regulation by interacting with and mediating
degradation of the BCL2 mRNA. The zinc finger motifs of
ZFP36L1 are evidently required for this interaction. These
findings are consistent with previous observations on apoptosis
induced by ZFP36 family members, specifically the requirement
for a functional zinc finger domain [13,14] and the apoptosis
rescue elicited by over-expression of exogenous BCL2 [14]. Given
the important role of BCL2 in normal and malignant B cell
Figure 4. Modulation of ZFP36L1 expression levels is associated with changes in BCL2mRNA levels in different cell types. (A) Western
blot analysis showing Zfp36L1 protein expression in wild-type, ZFP36L1 ShRNA and control empty lentivirus transduced BCL1 cells. Cell Signaling
Technology rabbit-anti-human ZFP36L1/L2 antibody was used to detect Zfp36l1 expression. An anti-HSP90 antibody was used as a control for
protein loading on the gel. (B) BCL2 mRNA degradation analysis following actinomycin D treatment in Zfp36l1-knockdown and control murine
leukemia BCL1 cells. qRT-PCR analysis of Bcl2 mRNA levels over a 4 hour time course in control (empty lentivirus transduced BCL1 cells) and zfp36l1-
knockdown BCL1 cells. Cells were treated with 5 mg/ml of actinomycin D for 0, 2, and 4 hours. The results are from 3 independent experiments and
show mean 6SEM. * = p,0.05 as determined by student T test. (C) ZFP36L1 and BCL2 mRNA levels were measured by qRT-PCR in BCL1, ACHN and
Ramos cells. Lentiviral mediated ZFP36L1 ShRNA was used to knockdown ZFP36L1 mRNA levels in BCL1, ACHN and Ramos cells. qRT-PCR analysis was
carried out as described in Methods. Control cells were transduced with lentivirus containing scramble sequence (BCL1, ACHN) or empty lentivirus
(Ramos). Mean6SEM for triplicate samples are shown. These results are representative of at least 2 independent experiments done on each cell type.
(D) BCL2 protein expression in ZFP36L1 ShRNA transduced or empty lentivirus (con) transduced Ramos cells. An anti-HSP90 antibody was used as a
control for protein loading on the gel. (E) Following either ZFP36L1 or control siRNA oligonucleotide transfection, Ramos cells were treated with
ionophore (A23187, 150 nM) and, 24 h later, MTT levels were measured. The results shown are from 4 independent experiments, mean 6SEM are
shown. * = p,0.05 as determined by student T test.
doi:10.1371/journal.pone.0102625.g004
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survival [33], identification of BCL2 mRNA as a target for
ZFP36L1 may provide a mechanism for a number of experimental
observations implicating ZFP36L1 in apoptosis induction in
malignant B cells [10,11]. Although not further investigated in
the present study, it is quite likely that BCL2 mRNA, inferred from
regulatory network reconstruction as a target for the ZFP36
protein, is also regulated in an analogous fashion by this ZFP36
family member. Having established the ZFP36L1/BCL2 axis at a
mechanistic level, it will be very important to further evaluate the
biological importance of this axis in malignant B cell survival and
death in future studies.
In addition to AU-rich RNA binding proteins, microRNAs
(miRNA), notably miR-15 and miR-16, have also previously been
shown to target the BCL2 mRNA for destruction via binding to
AREs [38,39]. The observation that miR-16 requires the
cooperative activity of ZFP36 family members in order to bind
to AREs [40] is entirely consistent with our own observations on
direct functional binding of ZFP36L1 to the 39UTR of BCL2
mRNA. Finally, we note that all four RNA-binding proteins
(AUF1, nucleolin, HUR, ZFP36L1) that are now known to target
AREs in the BCL2 39 UTR are themselves capable of physical
association with each other via protein-protein interaction (see ref
[2]). Thus, the coordinate/cooperative activities of multiple RNA-
binding proteins that orchestrate the post-transcriptional ‘regu-
lome’ on BCL2 mRNA probably function in consort with miRNA
pathways as components of higher-order macromolecular com-
plexes.
In addition to BCL2, the inferred regulatory network for the
ZFP36 family proteins constructed in our study identified other
mRNAs encoding pro-survival proteins that may also function in
the apoptotic response elicited by ZFP36 family members. It is
noteworthy that these targets overlapped between different ZFP36
family members. The more global picture of inferred targets
(Fig. 2A) also revealed extensive overlap, but with each ZFP36
family member targeting its own unique set of mRNAs. It should
be noted that the MIC algorithm that was employed to infer target
mRNAs will only identify those that display a strong dependency
on the expression of ZFP36 family proteins. While these mRNAs
are likely to represent targets that are most strongly regulated by
ZFP36 proteins, there will undoubtedly be numerous other
mRNAs targets that are subject to dominant regulation of
expression via other post-transcriptional and transcriptional
mechanisms that are weakly influenced by ZFP36 proteins.
Nonetheless, this reconstructed regulatory network is consistent
with the partial redundancy of biological functions of the ZFP36
protein family. Whereas all three ZFP36 proteins elicit an
apoptosis response (typically observed in vitro), subtle differences
are evident, particularly in studies using mouse models on other
functions related to tumourigenesis. For example, mouse models
have provided evidence that ZFP36 family proteins can function
as tumour suppressor proteins in lymphoid malignancies. Deletion
of ZFP36L1 and ZFP36L2 was reported to promote T cell
leukemia in knockout mice by targeting notch1 mRNA [41]
Intriguingly, leukemia did not develop in single ZFP36L1 or
ZFP36L2 knockout mice [41]. In Em-Myc mice, a mouse model of
human Burkitt lymphoma, and also in human Burkitt lymphoma
versus non-Burkitt lymphomas, ZFP36 and ZFP36L1 were shown
to be transcriptionally repressed [42]. Moreover, ZFP36, but not
ZFP36L1, was shown to function as a tumour suppressor in the
Em-Myc model [42]. Notwithstanding the lack of tumour
suppressor function of ZFP36L1 in the Em-Myc mouse model,
other studies in human B-lymphoid malignancies have implicated
loss of ZFP36L1 function in disease pathogenesis. For example, in
a subset of human B cell malignancies there are interstitial
deletions of the ZFP36L1 locus at 14q24 [43] and, recent whole
genome sequencing of tumours from multiple myeloma patients
has identified regulatory-region and coding-region mutations in
the ZFP36L1 gene [44]. The comprehensive identification of
mRNA targets for ZFP36L1 (and for other members of this family)
Figure 5. ZFP36L1 mediates degradation of a 39 UTR BCL2 ARE.
(A) Transfection of ZFP36L1 or mutant ZFP36L1 into HEK293T cells
results in high level ZFP36L1 expression as shown by Western blot
analysis. Very low/absent levels of ZFP36L1 are found in empty vector
(pcDNA3) transfected HEK293T cells. (B) ZFP36L1 interacts with the
BCL2 ARE and mediates BCL2 ARE degradation. BCL2 39 UTR luciferase
reporter assay showing reduced luciferase values in HEK293T cells
transfected with ZFP36L1 and BCL2 ARE compared to values obtained
by co-transfection of BCL2 ARE with either an empty vector (pcDNA3) or
a zinc finger mutant ZFP36L1. The results show mean 6SEM for three
independent experiments. p,0.05 as determined by student T test. (C)
BCL2 39 UTR Luciferase reporter assay showing that ZFP36L1 requires
the BCL2 ARE core AU-rich element to effectively reduce luciferase
levels, whereas a BCl2 ARE construct with the core AU-rich element
removed is much less affected. The results show mean 6SEM for three
independent experiments, p,0.05 as determined by student T test.
doi:10.1371/journal.pone.0102625.g005
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should provide mechanistic insight into the role of these proteins in
malignancies of the B-lymphoid and other cell lineages.
Supporting Information
Figure S1 Production of bacterially expressed ZFP36L1
protein. Western blot showing recombinant human ZFP36L1
protein expression Lanes 1, 2 and 3 (Ve+): Positive controls
containing 5, 1 and 0.2 ml of total protein lysate from BL21 E.coli
cells, transformed with a recombinant pET15b vector containing
the human ZFP36L1 open reading frame. Lane 4 (Ve–): Negative
control containing 5 ml of lysates from E.coli BL21 cells,
transformed with an empty pET15b vector. Lanes 5, 6 and 7:
correspond to 5, 10 and 20 ml of ZFP36L1 protein (approximately
100 ng/ml) purified according to the protocol detailed in Materials
and Methods. Anti-ZFP36L1 antibody (Cell Signaling Technology
rabbit-anti-human ZFP36L1/L2 antibody) was used to detect
ZFP36L1 protein.
(TIF)
Figure S2 IL-3 mRNA levels are increased in BCL1 cells
transduced with a ZFP36L1 ShRNA. IL-3 mRNA levels were
measured by qRT-PCR in lentiviral mediated ZFP36L1 ShRNA
transduced BCL1 cells (see Fig. 4A) and cells transduced with
scramble sequence containing lentivirus. The results show mean
6SEM from 6 replicate samples.
(TIF)
Table S1 Inferred target mRNAs for ZFP36 family
members.
(XLS)
Table S2 Enrichment of Gene Ontology terms (Biolog-
ical Process) in inferred ZFP36 family target mRNAs.
(XLS)
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